Gastrointestinal Henoch-Schönlein purpura successfully treated with Mycophenolate Mofetil: Description of 2 case reports.
Journal
Medicine
ISSN: 1536-5964
Titre abrégé: Medicine (Baltimore)
Pays: United States
ID NLM: 2985248R
Informations de publication
Date de publication:
08 Jan 2021
08 Jan 2021
Historique:
received:
31
03
2020
accepted:
08
12
2020
entrez:
12
1
2021
pubmed:
13
1
2021
medline:
20
1
2021
Statut:
ppublish
Résumé
Henoch-Schönlein Purpura (HSP) is an acute small vessel vasculitis. It is the most common vasculitis in children. In majority of the cases, the disease is self-limited. Relapses can occur, in particular during the first year of the disease. There is no consensus on a specific treatment. The efficacy and safety of steroidal treatment in treating HSP is still controversial. Immunosuppressive treatment of HSP nephritis is used in patients with severe renal involvement (nephrotic range proteinuria and/or progressive renal impairment). The literature on immunosuppressive treatment of severe HSP without kidney involvement is scanty. We report 2 case reports of 2 adolescents affected from Henoch-Schönlein Purpura and severe gastrointestinal involvement. Both patients presented a poor response to steroids treatment. The diagnosis of HSP was made according to the diagnostic criteria published by European League against Rheumatism and Pediatric Rheumatology European Society in 2006. In consideration of the recurrence of the Henoch Schönlein Purpura and the gastrointestinal involvement, we decided to start Mycophenolate Mofetil treatment. In both patients all clinical manifestations resolved in few days. In our cases of HSP with gastrointestinal involvement Mycophenolate Mofetil treatment has been very effective. This experience teaches us that immunosuppressive agents may be very useful to induce and maintain remission not only in renal involvement, but in all cases of persistent, recurrent, or complicated Henoch Schönlein Purpura in children.
Identifiants
pubmed: 33429774
doi: 10.1097/MD.0000000000024093
pii: 00005792-202101080-00050
pmc: PMC7793365
doi:
Substances chimiques
Enzyme Inhibitors
0
Mycophenolic Acid
HU9DX48N0T
Types de publication
Case Reports
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e24093Informations de copyright
Copyright © 2021 the Author(s). Published by Wolters Kluwer Health, Inc.
Déclaration de conflit d'intérêts
The authors have no conflicts of interest to disclose.
Références
Hetland LE, Susrud KS, Lindahl KH, et al. Henoch-Schonlein purpura: a literature review. Acta Derm Venereol 2017;97:1160–6.
He X, Yu C, Zhao P, et al. The genetics of Henoch–Schonlein purpura: a systematic review and meta-analysis. Rheumatol Int 2013;33:1387–95.
Kang Y, Park JS, Ha YJ, et al. Differences in clinical manifestations and outcomes between adult and child patients with Henoch-Schonlein purpura. J Korean Med Sci 2014;29:198–203.
Reid-Adam J. Henoch-Schonlein purpura. Pediatr Rev 2014;35:447–9.
Ozen S, Pistorio A, Iusan SM, et al. EULAR/PRINTO/PRES criteria for Henoch-Schonlein purpura, childhood polyarteritis nodosa, childhood Wegener granulomatosis and childhood Takayasu arteritis: Ankara 2008. Part II: Final classification criteria. Ann Rheumatic Dis 2010;69:798–806.
Elsevier, Cassidy JT, Petty RE, Laxer RM, et al. Textbook of Pediatric Rheumatology. 7th ed2011.
Wei-Te L, Po-Li T, Szu-Hung C, et al. Incidence and risk factors for recurrent Henoch-Schönlein purpura in children from a 16-year nationwide database. Pediatr Rheumatol Online J 2018;16:25.
Rao S, Singhal V, Kamath N. Henoch Schonlein Purpura: classification and management—an update. Karnataka Paediatric J 2012;26:2–5.
Fotis L, Tuttle PV, Baszis KW, et al. Azathioprine therapy for steroid resistant Henoch Schonlein Purpura: a report of 6 cases. Pediatr Rheumatol Online J 2016;14:37.
Tan J, Tang Y, Zhong Z, et al. The efficacy and safety of immunosuppressive agents plus steroids compared with steroids alone in the treatment of Henoch–Schonlein purpura nephritis: a meta-analysis. Int Urol Nephrol 2019;51:975–85.
Ronkainen J, Koskimies O, Ala-Houhala M, et al. Early prednisone therapy in Henoch Schonlein purpura: a randomized, double blind, placebo control trial. J Pediatr 2006;149:241–7.
Hetland E, Kjærsti Sørensen S, Hein Lindahl K, et al. Henoch-schonlein purpura: a literature review. Liv Acta Derm Venereal 2017;97:1160–6.
Nikibakhsh AA, Mahmoodzadeh H, Karamyyar M, et al. Treatment of complicated Henoch-Schonlein Purpura with Mycophenolate Mofetil: a retrospective case series report. Int J Rheumatol 2010;2010:254316.
Martin S, Cramer CH, Heikenen J, et al. Gastrointestinal symptoms of Henoch-Schonlein purpura treated with mycophenolate mofetil. J Pediatr Gastroenterol Nutr 2006;43:245–7.
Uluca U, Ece A, Sen V, et al. Management of intestinal bleeding with single-dose cyclophosphamide in Henoch-Schonlein Purpura. Pediatr Int 2015;57:498–500.
Rodriguez-Smith J, Brunner HI. Update on the treatment and outcome of systemic lupus erythematous in children. Curr Opin Rheumatol 2019;31:464–70.
Filler G, Hansen M, LeBlanc C, et al. Pharmacokinetics of mycophenolate mofetil for autoimmune disease in children. Pediatr Nephrol 2003;18:445–9.
Hu W, Liu C, Xie H, et al. Mycophenolate mofetil versus cyclophosphamide for inducing remission of ANCA vasculitis with moderate renal involvement. Nephrol Dial Transplant 2008;23:1307–12.
Hackl A, Becker J, Körner U, et al. Mycophenolate mofetil following glucocorticoid treatment in Henoch–Schönlein purpura nephritis: the role of early initiation and therapeutic drug monitoring. Pediatr Nephrol 2017;33:619–29.
Wang H, Zhang B, Li S, et al. Clinical outcome in pediatric refractory gastrointestinal Henoch-Schonlein purpura treated with mycophenolate mofetil. Eur J Pediatr 2020;179:1361–6.
Foster H and Brogan P. Paediatric Rheumatology ( Oxford Specialist Handbooks in Paediatrics ), 2012.